Vaxart, Inc.

Today, Vaxart reported its third quarter results and provided a business update. Vaxart expects to complete enrollment of the 400-participant sentinel cohort for the COVID-19 Phase 2b study in November 2024, held productive conversations with the FDA on its data for potential correlates of protection for its norovirus program and has a solid financial position that enables the company to attain multiple regulatory and clinical milestones. Read more in our press release here: https://lnkd.in/dKkBfrv9 #pillthatmovestheneedle #COVID-19 #norovirus

Vaxart will provide a business update and report third quarter 2024 financial results after the market close on Wednesday, November 13, 2024. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. Investors may submit written questions in advance of the conference call to [email protected]. Join us on our webcast: https://lnkd.in/e-wQiqGM

Today, we recognize the bravery, sacrifice, and commitment of our veterans. Their service has shaped our nation and safeguarded our freedoms. Today and every day, we say thank you. ? #VeteransDay

Today is Election Day! At Vaxart, we’re dedicated to improving public health and building a better future for all. Today, we encourage you to vote and help shape the future.

Vaxart is excited to present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the The World Vaccine Congress taking place October 28-31, 2024, in Barcelona. James Cummings will present a clinical update on our oral vaccine candidate and Sean Tucker will present data on how our oral norovirus vaccine candidate induces cross-reactivity and clinical data on protection against infection in humans. Read more about our upcoming presentations here: https://lnkd.in/evYBKsgh #WVCEU #VaccineDevelopment #pillthatmovestheneedle #norovirus #COVID-19

We are excited to present research demonstrating the potential of our norovirus oral pill vaccine candidate at IDWeek taking place October 16-19, 2024, at the Los Angeles Convention Center. ? Sean Tucker and Lam Nguyen, M.D. will each present our clinical research from our Phase 2 challenge study and Phase 1 trial focused on lactating mothers, respectively, underscoring our commitment to this serious unmet need. ? Read more about our upcoming presentations here https://lnkd.in/emHasJ8B ? #pillthatmovestheneedle #norovirus

Vaxart celebrates #IndigenousPeoplesDay and the rich histories, cultures, and contributions of Indigenous communities.?We support building a future that respects and uplifts Indigenous peoples and their voices. #CulturalHeritage #Inclusion #Vaxart #PillThatMovesTheNeedle

We are excited to announce that the first participant has been dosed in the sentinel cohort of a Phase 2b study evaluating our COVID-19 oral pill vaccine candidate against an mRNA comparator. ? The 400-participant sentinel cohort is funded as part of Project NextGen, an initiative led by Biomedical Advanced Research and Development Authority (BARDA) and National Institute of Allergy and Infectious Diseases (NIAID), with the trial valued at up to $456 million. ? The sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart’s next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator. ? Upon review of the safety data, the trial will proceed to enroll 10,000 additional participants. ? Read more in our press release that we issued last week: https://lnkd.in/eFv3fKcN ? #PillThatMovesTheNeedle #COVID19 #BARDA #NIAID #vaccines #globalhealth

Our CMO, James Cummings, discussed our innovative COVID-19 platform in a two-part interview with Contagion_Live. During the interview, Dr. Cummings highlighted our recently initiated COVID-19 Phase 2b study under Project NextGen, the benefits of our oral vaccine in potentially enhancing immune response and our goal of transforming public health. Part 1: https://lnkd.in/d5Kneb4k Part 2: https://lnkd.in/e73jYQXb

Our partner Vaxart, Inc. announced the initiation of the sentinel cohort of its Phase 2b clinical trial, which aims to determine the efficacy, safety, and immunogenicity of Vaxart’s oral COVID-19 vaccine candidate compared to a traditional, FDA-approved vaccine. This effort is a part of overarching work supported under #ProjectNextGen to create vaccines that work better than those currently available. Earlier this year, we announced the initial work with Vaxart, along with other partners, to plan and execute multiple Phase 2b clinical trials. Learn more about our efforts to protect Americans against COVID-19: https://ow.ly/vz0a50Tzvc8